PT-141 (Bremelanotide): The Peptide for Sexual Health and Low Libido

What Is PT-141 (Bremelanotide)?

PT-141, known by its pharmaceutical name bremelanotide, is a synthetic peptide that has emerged as one of the most promising treatments for sexual dysfunction and low libido in both men and women. Unlike traditional medications for sexual health — such as sildenafil (Viagra) or tadalafil (Cialis) — PT-141 does not work by increasing blood flow to the genitals. Instead, it targets the central nervous system, specifically the melanocortin receptors in the brain, to directly stimulate sexual desire at its neurological source.

Originally derived from research into the tanning peptide Melanotan II, PT-141 was discovered almost by accident when male participants in early clinical trials reported unexpected and pronounced increases in sexual arousal. This serendipitous finding launched a decades-long research effort that culminated in the FDA's approval of bremelanotide under the brand name Vyleesi in June 2019, specifically for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.

The significance of PT-141 cannot be overstated. For the first time, clinicians had a pharmacological tool that addressed the desire component of sexual function, not merely the mechanical aspects. This distinction has made PT-141 one of the most discussed peptides in both mainstream medicine and the broader peptide therapy community.

How PT-141 Works: The Melanocortin Receptor Pathway

To understand why PT-141 represents such a paradigm shift in sexual health treatment, it helps to understand the neuroscience behind sexual desire. Arousal and libido are not purely physical responses — they begin in the brain, mediated by a complex interplay of neurotransmitters, hormones, and receptor pathways.

The Melanocortin System

The melanocortin system is a group of peptide hormones and their corresponding receptors (MC1R through MC5R) that regulate a wide range of physiological processes, including:

• Skin pigmentation (MC1R)
• Adrenal function and cortisol release (MC2R)
• Energy homeostasis, appetite, and weight regulation (MC3R, MC4R)
• Exocrine gland secretion (MC5R)
• Sexual function and arousal (MC3R, MC4R)

PT-141 is a non-selective agonist of the melanocortin receptors, with particularly strong activity at the MC3R and MC4R subtypes. These receptors are densely expressed in the hypothalamus and other brain regions that govern sexual behavior, reward, and motivation.

The Neural Pathway of Desire

When PT-141 binds to MC4R receptors in the hypothalamus, it initiates a cascade of downstream signaling that increases the activity of dopaminergic and oxytocinergic pathways — two neurotransmitter systems intimately linked to pleasure, bonding, and sexual motivation. This is fundamentally different from PDE5 inhibitors like Viagra, which act peripherally on vascular smooth muscle.

In simpler terms: PT-141 makes you want to have sex, while Viagra makes it physically possible. These are two very different clinical problems, and for millions of people whose primary issue is diminished desire rather than erectile mechanics, PT-141 addresses the root cause.

"PT-141 is the first drug that targets the brain's desire circuitry rather than genital blood flow. It represents a fundamental shift in how we think about treating sexual dysfunction." — Dr. Sheryl Kingsberg, Division Chief of Behavioral Medicine, University Hospitals Cleveland Medical Center

Pharmacokinetics

After subcutaneous injection, PT-141 reaches peak plasma concentration within approximately one hour. Its effects on sexual desire typically begin within 30-60 minutes and can last for up to 24-72 hours in many patients, though the peak effect window is generally 2-6 hours post-injection. The peptide has a half-life of approximately 2.7 hours, but its neurological effects persist well beyond the clearance of the drug itself, suggesting that it triggers a sustained change in receptor sensitivity or downstream signaling.

PT-141 for Women: HSDD and the Vyleesi Approval

The FDA approval of PT-141 as Vyleesi was a landmark moment for women's sexual health. Hypoactive sexual desire disorder (HSDD) — defined as a persistent lack of sexual thoughts, fantasies, and desire that causes personal distress — affects an estimated 10% of premenopausal women in the United States, roughly 6 million individuals. Until PT-141, treatment options were extremely limited.

Clinical Trial Results in Women

The FDA approval was based on two pivotal Phase 3 clinical trials (RECONNECT studies) involving over 1,200 premenopausal women with HSDD. Key findings included:

• Statistically significant increase in the number of satisfying sexual events (SSEs) compared to placebo
• Meaningful improvement in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score, which measures the personal distress associated with low sexual desire
• Rapid onset — effects were observed within the first dose for many participants
• On-demand dosing — unlike daily medications such as flibanserin (Addyi), Vyleesi is used only when needed, at least 45 minutes before anticipated sexual activity

In the clinical data, approximately 25% of women treated with bremelanotide reported a clinically meaningful increase in desire, compared to about 17% in the placebo group. While the absolute difference may seem modest, it is important to consider the profound impact that restored sexual desire has on quality of life, self-esteem, and intimate relationships.

Why Vyleesi Matters for Women's Health

The approval of Vyleesi was significant not just pharmacologically but culturally. For decades, women's sexual health was under-researched and under-treated compared to men's. The existence of dozens of options for male erectile dysfunction alongside virtually nothing for female desire disorder highlighted a glaring disparity in clinical research priorities.

PT-141's mechanism of action — targeting central desire pathways rather than genital blood flow — aligned with the clinical reality that most women's sexual complaints center on wanting rather than functioning. Many clinicians now view bremelanotide as a first-line pharmacological option for premenopausal HSDD when behavioral and hormonal interventions have been insufficient.

Off-Label Use in Postmenopausal Women

While Vyleesi is FDA-approved only for premenopausal women, many providers prescribe PT-141 off-label for postmenopausal women experiencing HSDD or general sexual desire decline associated with hormonal changes. Emerging clinical experience suggests comparable efficacy in this population, though large-scale postmenopausal trials have not yet been completed. Postmenopausal women often benefit most when PT-141 is combined with low-dose hormone replacement therapy (HRT) to address both the neurological and hormonal components of desire.

PT-141 for Men: Beyond Erectile Dysfunction

Although PT-141 is not yet FDA-approved for any male indication, it has been extensively studied in men and is widely used off-label by peptide therapy clinics for male sexual dysfunction, particularly in cases where traditional PDE5 inhibitors are insufficient or contraindicated.

Clinical Evidence in Male Sexual Dysfunction

Multiple clinical trials have evaluated PT-141 in men with erectile dysfunction (ED). In a notable Phase 2B study, bremelanotide administered via subcutaneous injection demonstrated:

• Significant improvement in erectile function scores compared to placebo
• Increased sexual desire alongside improved erectile response — a dual benefit not seen with PDE5 inhibitors
• Efficacy in men who had failed to respond to sildenafil, suggesting a complementary or alternative mechanism of action
• Effectiveness in men with psychogenic ED, where the primary barrier is psychological rather than vascular

This last point is particularly important. A significant percentage of men under 40 who present with ED have psychogenic rather than organic causes — performance anxiety, relationship stress, depression, or pornography-related desensitization. Because PT-141 acts on central desire and arousal circuits, it may address these psychological barriers in a way that Viagra cannot.

The Desire-Performance Connection

One of the most commonly reported benefits among men using PT-141 is a subjective increase in sexual desire and motivation that goes beyond simple erectile improvement. Many men describe feeling a "primal" or "instinctive" drive that they had lost, accompanied by heightened sensitivity to sexual stimuli. This aligns with the drug's mechanism of action on hypothalamic dopamine and oxytocin pathways.

For men who experience adequate erectile function but diminished libido — a common presentation in men over 40, men on certain medications (SSRIs, opioids, finasteride), or men with suboptimal testosterone levels — PT-141 offers a targeted intervention that neither testosterone replacement nor PDE5 inhibitors fully address.

"I've had patients tell me that PT-141 brought back a dimension of sexual experience they thought was gone forever — not just the ability to perform, but the genuine desire. That's something Viagra was never designed to do." — Dr. Jason Kovac, urologist and male sexual health specialist

Combining PT-141 with Other Therapies

Many forward-thinking clinicians now use PT-141 as part of a multi-modal approach to male sexual dysfunction, combining it with:

• Low-dose PDE5 inhibitors — addressing both central desire and peripheral blood flow
• Testosterone replacement therapy (TRT) — optimizing hormonal milieu while boosting neurological desire
• Oxytocin nasal spray — enhancing bonding and emotional connection during intimacy
• Psychotherapy or couples counseling — addressing underlying relational or psychological factors

This combination approach often yields results superior to any single intervention, particularly in complex cases involving multiple contributing factors.

PT-141 vs. Viagra vs. Cialis: Understanding the Differences

One of the most common questions patients ask is how PT-141 compares to the well-known erectile dysfunction medications. The answer requires understanding that these drugs target fundamentally different aspects of sexual function.

Mechanism of Action Comparison

PDE5 Inhibitors (Viagra/Cialis): These drugs work by inhibiting phosphodiesterase type 5 (PDE5), an enzyme that breaks down cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of penile blood vessels. By preserving cGMP levels, they promote vasodilation and increased blood flow to the penis, facilitating erection in response to sexual stimulation. Crucially, they do not create sexual desire — they only enable the physical response when desire and stimulation are already present.

PT-141 (Bremelanotide): As discussed, PT-141 acts centrally on melanocortin receptors in the hypothalamus, activating dopaminergic and oxytocinergic pathways that govern sexual motivation and desire. It does not directly affect genital blood flow, though increased central arousal often leads to improved peripheral sexual response as a secondary effect.

Head-to-Head Comparison

Feature	PT-141	Viagra (Sildenafil)	Cialis (Tadalafil)
Target	Brain (melanocortin receptors)	Penis (PDE5 enzyme)	Penis (PDE5 enzyme)
Primary Effect	Increases desire/libido	Improves erections	Improves erections
Works for Women	Yes (FDA-approved)	Minimal evidence	Minimal evidence
Onset	30-60 minutes	30-60 minutes	30-60 minutes
Duration	Up to 24-72 hours	4-6 hours	Up to 36 hours
Administration	Subcutaneous injection	Oral tablet	Oral tablet
Blood Pressure Effects	May raise BP slightly	Lowers BP	Lowers BP
Nitrate Interaction	No contraindication	Dangerous — contraindicated	Dangerous — contraindicated

One of the most clinically significant distinctions is that PT-141 does not carry the cardiovascular contraindications that PDE5 inhibitors do. Men who take nitrates for heart conditions — and therefore cannot safely use Viagra or Cialis — may be candidates for PT-141. However, PT-141 can cause transient increases in blood pressure, so careful cardiovascular screening is still essential.

When to Choose PT-141 Over PDE5 Inhibitors

PT-141 may be preferred when:

• The primary complaint is low desire/libido rather than erectile difficulty
• The patient takes nitrate medications and cannot safely use PDE5 inhibitors
• PDE5 inhibitors have been ineffective or poorly tolerated
• The patient is a woman with HSDD
• ED is primarily psychogenic in nature
• The patient desires a longer duration of effect

Conversely, PDE5 inhibitors remain first-line for men whose primary issue is vascular ED with preserved desire, as they have a longer safety track record and more convenient oral administration.

Administration, Dosing, and Side Effects

Administration Route

PT-141 is administered via subcutaneous injection, typically into the abdomen or thigh. The Vyleesi autoinjector makes self-administration relatively straightforward for most patients. In peptide therapy clinics, PT-141 is often dispensed as a reconstituted lyophilized powder with insulin syringes for subcutaneous injection.

Some compounding pharmacies and clinics also offer PT-141 as a nasal spray, though this route was abandoned during the original Palatin Technologies clinical development program due to inconsistent bioavailability and concerns about blood pressure effects. Newer nasal formulations have been developed with improved delivery systems, and some providers report good clinical results with intranasal dosing, though it remains off-label.

Dosing Protocols

The FDA-approved dose of Vyleesi is 1.75 mg subcutaneously, administered at least 45 minutes before anticipated sexual activity. Key dosing guidelines include:

• Maximum frequency: No more than one dose per 24-hour period
• Maximum monthly doses: The FDA label recommends no more than 8 doses per month
• Timing: Administer 45 minutes to several hours before desired effect
• Do not use daily: PT-141 is an on-demand medication, not a daily regimen

In clinical practice, many peptide therapy providers use a range of doses depending on patient response:

• Starting dose: 0.5-1.0 mg to assess tolerance
• Standard dose: 1.0-2.0 mg for most patients
• Higher dose: Up to 2.5 mg in patients with insufficient response at lower doses

Individual response to PT-141 varies significantly. Some patients experience dramatic effects at low doses, while others require higher amounts. A qualified provider will typically start low and titrate upward based on response and tolerance.

Common Side Effects

PT-141 is generally well-tolerated, but several side effects are commonly reported:

• Nausea — the most common side effect, reported by approximately 40% of women and 20% of men in clinical trials. It is typically mild, transient (lasting 1-2 hours), and decreases with subsequent doses. Taking an anti-nausea medication 30 minutes before PT-141 can help.
• Facial flushing — reported by about 20% of patients, related to melanocortin receptor activation in vascular tissue
• Headache — occurs in approximately 10-15% of patients
• Injection site reactions — mild redness or bruising at the injection site, typically resolving within 24 hours
• Transient blood pressure elevation — PT-141 can cause a small, temporary increase in blood pressure (typically 5-10 mmHg systolic), usually resolving within 12 hours
• Skin hyperpigmentation — with repeated use, some patients notice slight darkening of the skin, particularly in the facial area, related to MC1R activation. This is cosmetically minor and generally reversible upon discontinuation.

Contraindications and Precautions

PT-141 should be used with caution or avoided in the following situations:

• Uncontrolled hypertension — due to the transient blood pressure elevation
• Cardiovascular disease — patients with significant heart disease should be carefully evaluated
• Pregnancy or breastfeeding — PT-141 is not studied in pregnant or nursing women and should be avoided
• Concurrent use with naltrexone — melanocortin and opioid pathways interact, and concurrent use may alter efficacy
• History of priapism — though rare with PT-141, any pro-sexual medication should be used cautiously in men with a history of prolonged erections

The Psychology of Desire: Why PT-141 Fills a Critical Gap

To fully appreciate the clinical significance of PT-141, it helps to understand why low sexual desire is such a complex and underserved medical problem. Sexual desire is not a simple on/off switch — it emerges from the interaction of neurochemical signaling, hormonal milieu, psychological state, relational dynamics, and even cultural conditioning. For decades, medicine lacked the tools to address the neurochemical component directly.

The Biopsychosocial Model of Desire

Modern sexual medicine conceptualizes desire through the biopsychosocial model, which recognizes that sexual function arises from the interplay of biological, psychological, and social factors. PT-141 addresses the biological/neurochemical dimension — the melanocortin-mediated arousal circuitry — but its effects often cascade into psychological and relational improvements as well. Patients who recover sexual desire frequently report improvements in self-esteem, body image, emotional intimacy with partners, and overall life satisfaction that extend far beyond the bedroom.

This ripple effect underscores why treating low desire is not a "lifestyle" concern but a legitimate medical intervention with broad quality-of-life implications. Studies have consistently shown that untreated HSDD is associated with higher rates of depression, anxiety, and relationship dissolution — outcomes that carry their own significant health consequences.

Medication-Induced Sexual Dysfunction

One of the most common and underappreciated causes of low sexual desire is medication side effects. Several widely prescribed drug classes are known to suppress libido, including:

• Selective serotonin reuptake inhibitors (SSRIs) — the most commonly prescribed antidepressants, which cause sexual dysfunction in 40-70% of users
• Hormonal contraceptives — oral contraceptive pills can suppress free testosterone and reduce desire in some women
• Opioid pain medications — chronic opioid use suppresses the hypothalamic-pituitary-gonadal axis
• 5-alpha reductase inhibitors — finasteride and dutasteride, used for hair loss and prostate conditions
• Beta-blockers and certain antihypertensives
• GnRH agonists and antiandrogens — used in prostate cancer and endometriosis treatment

For patients who cannot discontinue these medications, PT-141 offers a targeted intervention that works independently of the hormonal and serotonergic pathways these drugs affect. Its mechanism of action through melanocortin receptors provides a unique bypass around medication-induced desire suppression, making it particularly valuable in this growing patient population.

The Regulatory and Access Landscape in 2026

FDA-Approved Vyleesi

The brand-name Vyleesi autoinjector remains FDA-approved for premenopausal HSDD in women. However, its uptake has been slower than initially anticipated, for several reasons:

• Cost: Vyleesi carries a list price of approximately $900 for a four-dose pack, and insurance coverage has been inconsistent
• Injection requirement: Many patients and providers are more comfortable with oral medications
• Nausea: The high incidence of nausea has limited adherence in some patients
• Marketing challenges: Discussing female sexual desire remains culturally sensitive, affecting both direct-to-consumer advertising and provider-patient conversations

Compounded PT-141

Due to the high cost of brand-name Vyleesi, many patients access PT-141 through compounding pharmacies, where the peptide can be obtained at a fraction of the branded price — typically $50-150 per multi-dose vial. However, the regulatory landscape for compounded peptides has shifted significantly.

The FDA's 2024-2025 enforcement actions against certain compounded peptides (most notably tirzepatide and semaglutide) have created uncertainty about the future availability of compounded PT-141. As of early 2026, PT-141 remains available through licensed compounding pharmacies operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, but patients and providers should stay informed about any regulatory changes.

Insurance Coverage

Insurance coverage for PT-141/Vyleesi varies widely:

• Commercial insurance: Some plans cover Vyleesi with prior authorization, often requiring documentation of failed behavioral interventions and/or flibanserin therapy
• Medicare/Medicaid: Generally not covered, as sexual dysfunction treatments are often excluded
• Compounded PT-141: Almost never covered by insurance and is typically a cash-pay expense

Patients should work with their provider's office to explore manufacturer patient assistance programs, which can reduce the out-of-pocket cost of Vyleesi significantly for qualifying individuals.

Finding a Qualified PT-141 Provider

If you're considering PT-141 therapy, finding the right provider is essential. Not all healthcare professionals are familiar with melanocortin-based therapies, and the quality of care can vary significantly between providers.

What to Look for in a Provider

• Board certification in a relevant specialty (endocrinology, urology, gynecology, sexual medicine, or functional/integrative medicine)
• Experience with peptide therapies — ask how many patients they have treated with PT-141 specifically
• Comprehensive evaluation — a good provider will assess hormonal status (testosterone, estrogen, thyroid), psychological factors, relationship dynamics, and medication history before prescribing
• Legitimate pharmacy sources — the provider should use FDA-registered compounding pharmacies or prescribe brand-name Vyleesi
• Follow-up protocols — ongoing monitoring of blood pressure, response, and side effects
• Multi-modal approach — willingness to combine PT-141 with hormonal, psychological, and lifestyle interventions as appropriate

Red Flags to Avoid

• Providers who prescribe PT-141 without a thorough evaluation
• Online-only clinics with no medical history review or physical examination
• "Peptide mills" offering dozens of peptides with minimal medical oversight
• Any provider dispensing PT-141 from non-pharmacy sources or without proper storage (cold chain)
• Claims of guaranteed results or unrealistic expectations

Using PeptideProbe to Find a Provider

PeptideProbe's directory includes clinics and providers who offer PT-141 therapy across the United States. Our listings include verified credentials, patient reviews, and detailed information about each provider's approach to sexual health treatment. You can filter by location, specialty, and specific peptide offerings to find a provider who meets your needs.

Patient Experience: What to Expect When Starting PT-141

Understanding what the PT-141 experience is actually like can help set realistic expectations and reduce anxiety about starting treatment.

The First Dose

Most providers recommend taking your first dose on a day when you have no time pressure and can observe your response in a relaxed setting. The injection itself is a small subcutaneous shot — similar to an insulin injection — and causes minimal discomfort. Within 30-60 minutes, many patients describe a gradual onset of warmth, heightened sensory awareness, and a growing sense of sexual interest that feels natural rather than forced. Unlike the mechanical response to Viagra, the experience with PT-141 is often described as a restoration of desire that feels organic and internally motivated.

Nausea, if it occurs, typically begins within the first hour and resolves within 1-2 hours. Many providers recommend having an anti-nausea medication on hand for the first few doses, as nausea tends to diminish with subsequent use as the body acclimatizes to the peptide.

Building a Treatment Routine

Unlike daily medications, PT-141 is used on demand — typically 1-3 times per week depending on your provider's recommendations and your personal needs. Many patients develop a routine of administering the injection 1-2 hours before anticipated intimacy, though the extended duration of effect (up to 24-72 hours in many users) provides flexibility. Over time, many patients report that lower doses become sufficient as their bodies become more responsive to the melanocortin activation, suggesting a sensitization effect that is the opposite of the tolerance seen with many other medications.

The Future of PT-141 and Melanocortin-Based Therapies

PT-141 represents just the beginning of melanocortin-targeted sexual health therapeutics. Several exciting developments are on the horizon:

Next-Generation Melanocortin Agonists

Pharmaceutical companies are developing more selective MC4R agonists that may retain the pro-sexual effects of PT-141 while reducing side effects like nausea and blood pressure elevation. By targeting MC4R more precisely and avoiding activation of MC1R (pigmentation) and other subtypes, these next-generation compounds could offer improved tolerability profiles.

Oral Formulations

One of the barriers to PT-141 adoption has been the injection requirement. Research into oral peptide delivery systems, including enteric-coated tablets and sublingual formulations, may eventually enable non-injectable administration of bremelanotide or its analogs. Several biotech companies have reported promising preclinical data for oral melanocortin agonists as of 2025-2026.

Combination Therapies

The future of sexual health treatment is likely to involve carefully designed combination protocols. Researchers are investigating fixed-dose combinations of melanocortin agonists with other pro-sexual compounds, including low-dose oxytocin, dopamine modulators, and even micro-dose PDE5 inhibitors, in single-injection or oral formulations.

Male-Specific Indications

Several clinical trials are underway or planned for PT-141 in male-specific indications, including SSRI-induced sexual dysfunction, low libido associated with testosterone deficiency, and psychogenic erectile dysfunction. A successful Phase 3 trial could lead to a formal male indication, dramatically expanding the potential patient population and improving insurance coverage.

Frequently Asked Questions About PT-141

How quickly does PT-141 work?

Most patients notice the onset of effects within 30-60 minutes of subcutaneous injection. The peak effect typically occurs 1-3 hours after dosing, with residual effects lasting up to 24-72 hours in many individuals.

Can PT-141 be used alongside Viagra or Cialis?

Yes, many providers combine PT-141 with low-dose PDE5 inhibitors for men. This approach addresses both central desire (PT-141) and peripheral erectile function (PDE5 inhibitor) simultaneously. However, blood pressure should be monitored, as both classes can affect cardiovascular parameters.

Is PT-141 addictive?

There is no evidence that PT-141 is physically addictive or creates dependence. It does not act on opioid receptors or traditional addiction pathways. However, any medication that enhances pleasurable experiences carries a theoretical risk of psychological habituation, and it should be used as prescribed.

Does PT-141 work if I have normal libido?

PT-141 is indicated for individuals with clinically low desire. Using it in the absence of sexual dysfunction is considered off-label and is generally not recommended. There is limited data on its effects in individuals with normal sexual function.

Will PT-141 make me tan?

Slight skin darkening is possible with repeated use due to MC1R activation. This effect is generally subtle and reversible upon discontinuation. It is much less pronounced than with Melanotan II, from which PT-141 was derived, because PT-141 has reduced MC1R activity.

How long can I use PT-141?

There are no established long-term safety limits for PT-141 use. In clinical trials, bremelanotide was studied for up to 18 months without unexpected safety signals. However, the FDA labeling for Vyleesi does not specify a maximum duration of use. Work with your provider to establish an appropriate long-term plan.

Conclusion: Is PT-141 Right for You?

PT-141 represents a genuine breakthrough in sexual health pharmacology — the first medication to target the brain's desire circuitry rather than relying solely on peripheral blood flow mechanisms. For women with HSDD and men with desire-related sexual dysfunction, it offers a mechanism of action that no other available medication provides.

However, PT-141 is not a magic bullet. Sexual dysfunction is multifactorial, involving hormonal, psychological, relational, and lifestyle components. The best outcomes are achieved when PT-141 is used as part of a comprehensive treatment plan guided by a knowledgeable provider who takes the time to understand your unique situation.

If low libido or diminished sexual desire is affecting your quality of life and relationships, PT-141 may be worth discussing with a qualified healthcare provider. Use PeptideProbe's directory to find a vetted clinic in your area that offers bremelanotide therapy as part of a personalized sexual health program.

Medical Disclaimer: This article is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. PT-141/bremelanotide is a prescription medication that should only be used under the supervision of a licensed healthcare provider. PeptideProbe does not sell, prescribe, or endorse any specific medication or treatment.